News


All series


All News

AstraZeneca has submitted a&nbsp;supplemental new drug application to Japan&#39;s&nbsp;Pharmaceuticals and Medical Devices Agency for the use of the&nbsp;third-generation, irreversible EGFR tyrosine kinase inhibitor osimertinib (Tagrisso) in the frontline treatment of patients with&nbsp;inoperable or recurrent <em>EGFR</em>-positive non&ndash;small cell lung cancer.

Ribociclib (Kisqali) met its primary endpoint for progression-free survival (PFS) in premenopausal women with&nbsp;hormone-receptor (HR)&ndash;positive, HER2-negative (HR+/HER2-) advanced or metastatic breast cancer, according to topline results from the MONALEESA-7 trial, Novartis recently announced in a press release.

After granting a priority review to durvalumab (Imfinzi) in October for the treatment of patients&nbsp;with stage III, unresectable NSCLC whose disease has not progressed following platinum-based chemoradiation, the FDA is now reviewing results from the phase III PACIFIC trial, which have now&nbsp;been published in the print edition of the New England Journal Medicine.

Nilotinib (Tasigna) has been approved by the FDA for the treatment of pediatric patients with&nbsp;Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. The approval is both in the frontline setting and for those with&nbsp;resistance or intolerance to prior therapy, including imatinib.

The FDA has approved the IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets)&nbsp;tumor profiling assay, an in vitro diagnostic test that can identify more tumor biomarkers than any test previously reviewed by the agency.

PARP inhibitors offer great potential to improve outcomes for patients with ovarian cancer, and evidence will hopefully support their use in the first-line management of these patients,&nbsp;said Susana M. Campos, MD, a gynecologic oncologist at Dana-Farber Cancer Institute and an assistant professor at Harvard Medical School, during her talk at the 35th annual CFS<sup>&reg;</sup> meeting.

Richard Kim, MD, recently shared the treatment considerations and decisions he makes when treating patients with metastatic colorectal cancer, including the role of mutation testing and location of the tumor. Kim, associate professor of oncology, Moffitt Cancer Center, explained his treatment decisions based on 2 case scenarios during a&nbsp;<em>Targeted Oncology</em>&nbsp;live case-based peer perspectives dinner.

Andre Goy, MD,&nbsp;discusses the excitement surrounding novel therapies on the horizon in mantle cell lymphoma, as well as how the treatment paradigm will shift in the next 5 to 10 years.

Combining the PD-1 inhibitor nivolumab (Opdivo) with the novel IDO inhibitor&nbsp;BMS-986205 generated promising response rates&nbsp;in patients with advanced cervical or bladder cancers and similar adverse effects to what is seen with anti&ndash;PD-1 monotherapy, according to findings of an early-phase clinical trial presented by Jason J. Luke, MD, during the&nbsp;SITC 32nd Annual Meeting.

Hans-Joachim Schmoll, MD, discusses&nbsp;updated CHARTA findings, the current role of chemotherapy in patients with metastatic CRC, and his predictions for the future CRC treatment landscape.